Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Invested Capital (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Invested Capital data on record, last reported at $527.2 million in Q4 2025.

  • For Q4 2025, Invested Capital fell 29.43% year-over-year to $527.2 million; the TTM value through Dec 2025 reached $527.2 million, down 29.43%, while the annual FY2025 figure was $527.2 million, 29.43% down from the prior year.
  • Invested Capital reached $527.2 million in Q4 2025 per CLDX's latest filing, down from $598.4 million in the prior quarter.
  • Across five years, Invested Capital topped out at $838.6 million in Q1 2024 and bottomed at $182.3 million in Q2 2021.
  • Average Invested Capital over 5 years is $479.6 million, with a median of $424.3 million recorded in 2021.
  • Peak YoY movement for Invested Capital: surged 218.54% in 2024, then dropped 29.43% in 2025.
  • A 5-year view of Invested Capital shows it stood at $419.5 million in 2021, then dropped by 22.24% to $326.2 million in 2022, then surged by 31.57% to $429.2 million in 2023, then skyrocketed by 74.06% to $747.0 million in 2024, then decreased by 29.43% to $527.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were $527.2 million in Q4 2025, $598.4 million in Q3 2025, and $655.4 million in Q2 2025.